first look kick rais
view share trade higher better-than-expect result higher guidanc also think result ay lift
rest med-tech sector higher well sale growth show sequenti acceler includ orthoped busi
expect comment med-tech perform confer call start et estim sell day
minim impact growth rate ad less medic devic growth rate tune call et rate
equal weight question chat bloomberg im email kristen link call quarterli present
rais
jnj result ere ahead consensu estim specif revenu ere million ahead
street/bloomberg million ith ep compar ep rel estim beat larg
function higher revenu low er expect sg spend hich partial off-set higher tax rate see
varianc figur
organ sale driven pharmaceut busi medic devic unit consum sale
grow th modest expect difficult comparison babi given year ago re-launch activ
pharma vast major individu drug sale came consensu estim immunolog sale ere
 ith strong grow th stelara tremfya partial off-set expect remicad declin expect
due increas discounts/ rebat biosimilar discount oncolog sale ere darzalex
 note grow th comparison includ one-tim reimburs adjust year ago posit
impact op grow th zytiga sale us ere dow expect due gener
competit neurosci sale ere
devic busi unit came consensu ell devic grow th improv sequenti ith sale
quarter compar orthoped sale ere improv knee
sale improv -- global vs mainli attribut internationalthey still cite competit
pressur us us knee better still market global ex-fx hip
trauma spine dow advanc surgeri gener surgeri contact lens
surgic electrophysiolog sale ere strong grow th
consum busi unit perform ere bit mix rel consensu estim babi low er
dow reflect re-stock prior period also cite competit pressur aspac
declin ipe latam beauti also includ acquisit gain dr ci labo over-the-counter
also includ benefit zarbe
 rais guidanc -- organ sale guidanc adjust ep
 hich compar favor street current ep estim estim
addit non-gaap litig expens record third quarter despit rule
settlement made nine-month taken million litig expens found rather
interest though note product liabil claim record undiscount basi hen probabl liabil
incur amount liabil reason estim base exist inform actuari determin
estim applic also accru estim legal defens cost need defend matter hen
cost probabl reason estim extent advers verdict render
record accrual loss determin probabl reason estim
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog price target reflect sum-of-the-part analysi use pharma med tech consum peer
adjust rel grow th ep impli blend pe ep sinc share
trade averag pe market pe
risk may imped achiev barclay research valuat price nside risk greater pressur
biosimilars/gener increas pricing/reb advers litig rule pipelin failur competit product launch fda
action healthcar reform dilut deal integr issu upsid risk includ new product success success capit
deploy favor litig outcom competit product failur rotat defens stock
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc refinitiv reflect close price relev trade market hich may
last avail price time public
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur
issuer previou month
 employe non-execut director barclay plc director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic
issuer ithin next month
fa barclay bank plc and/or affili benefici ow ns class equiti secur issuer calcul
fb barclay bank plc and/or affili benefici ow ns long posit class equiti secur
issuer calcul accord ith eu regul
fc barclay bank plc and/or affili benefici ow ns short posit class equiti secur
issuer calcul accord ith eu regul
gd one analyst fundament credit coverag team member household financi interest
debt equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest
debt equiti secur issuer
 issuer benefici ow ns class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement ith issuer provis financi servic barclay
bank plc and/or affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or
 barclay bank plc and/or affili receiv non-invest bank relat compens includ compens
brokerag servic applic issuer ithin past month
 issuer past month invest bank client barclay bank plc and/or affili
issuer past month non-invest bank client secur relat servic barclay
bank plc and/or affili
 issuer past month non-invest bank client non-secur relat servic
barclay bank plc and/or affili
use
 partner director offic barclay capit canada inc preced month provid servic subject
compani remuner normal cours invest advisori trade execut servic
 barclay bank plc and/or affili corpor broker issuer
 barclay capit canada inc and/or affili receiv compens invest bank servic issuer
issuer corpor broker barclay plc
barclay bank plc and/or affili provid equiti advisori servic issuer
 equiti secur canadian issuer includ subordin vote restrict share
 equiti secur canadian issuer includ non-vot restrict share
guid barclay fundament equiti research rate system
coverag analyst use rel rate system hich rate stock overw eight equal eight underw eight see
definit rel compani cover analyst team analyst deem
industri industri coverag univers see list compani compris particular industri coverag univers pleas
go http //publicresearch barclay com
addit stock rate provid industri view hich rate outlook industri coverag univers posit
neutral neg see definit rate system use term buy hold sell equival rate
system investor care read entir research report includ definit rate infer content
rate alon
overweight stock expect outperform unw eight expect total return industri coverag univers
equal weight stock expect perform line ith unw eight expect total return industri coverag univers
invest horizon
underweight stock expect under-perform unw eight expect total return industri coverag univers
rate suspend rate target price suspend temporarili due market event made coverag
impractic compli ith applic regul and/or firm polici certain circumst includ invest
barclay plc act advisori capac merger strateg transact involv compani
posit industri coverag univers fundamentals/valu improv
neutral industri coverag univers fundamentals/valu steadi neither improv deterior
neg industri coverag univers fundamentals/valu deterior
distribut rate
barclay equiti research compani coverag
assign overw eight rate hich purpos mandatori regulatori disclosur classifi buy
